Skip to Main Content

Skip Nav Destination

Poster Sessions| November 16, 2004

Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy.

Mark S. Kaminski, MD,

Mark S. Kaminski, MD

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

Andrew D. Zelenetz, MD,

Andrew D. Zelenetz, MD

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

Oliver W. Press, MD,

Oliver W. Press, MD

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

Mansoor N. Saleh, MD,

Mansoor N. Saleh, MD

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

John P. Leonard, MD,

John P. Leonard, MD

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

Louis Fehrenbacher, MD,

Louis Fehrenbacher, MD

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

T. Andrew Lister, MD,

T. Andrew Lister, MD

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

Stewart Kroll, PhD,

Stewart Kroll, PhD *

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

Richard L. Wahl, MD,

Richard L. Wahl, MD *

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

Susan J. Knox, MD,

Susan J. Knox, MD *

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

Julie M. Vose, MD.

Julie M. Vose, MD.

¹Hematology, University of Michigan, Ann Arbor, MI, USA; ²Hematologic Oncology Lab, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Fred Hutchison Cancer Res Ctr, University of Washington, Seattle, WA, USA; ⁴Medicine, University of Alabama, Birmingham, AL, USA; ⁵Div Hematology, Oncology, Weill Medical College of Cornell University, New York, NY, USA; ⁶Div. of Research, Kaiser Permanente Medical Center, Vallejo, CA, USA; ⁷Medical Oncology, Saint Bartholemew’s Hospital, London, United Kingdom; ⁸Statistics, Corixa Corp., S. San Francisco, CA, USA; ⁹Div Nuclear Medicine, Johns Hopkins University, Baltimore, MD, USA; ¹⁰Radiation Oncology, Stanford University, Stanford, CA, USA and ¹¹Internal Medicine, University of Nebraska, Omaha, NE, USA.

Search for other works by this author on:

PubMed

Google Scholar

Blood (2004) 104 (11): 2631.

https://doi.org/10.1182/blood.V104.11.2631.2631

Abstract

Introduction: In 2001, we reported results of a pivotal study using BEXXAR in 60 patients (pts) with chemotherapy-refractory NHL who had been previously treated with a minimum of 2 protocol-specified chemotherapy regimens and had either not responded (72%) or had progressed within 6 mos of their last regimen (28%) (

JCO

.

2001

;

19

:

3918

). Enrollment occurred between Nov 1996 and Mar 1998, with a data cutoff for the initial report of 31 Jan 2001. Thirty-six pts had low-grade (LG) NHL, 23 pts had transformed LG NHL, and 1 pt had mantle cell NHL. The median number of prior chemotherapies was 4 (range, 2–13). The overall response rate was 65%. Twelve (20%) of 60 pts achieved a CR; median duration of CR was not reached with 47 mos’ follow-up. At the initial data cutoff, an independent review panel verified that 9 (75%) of 12 CR pts had ongoing responses, without further therapy, ranging from 2.7–4.0 yrs.

Methods: These 9 pts continue to be followed annually for investigator-assessed response. In addition, all 25 pts alive at the time of the last report continue to be followed for long-term safety (hypothyroidism, secondary cancers) for 10 yrs or until death. With a data cut-off of 1 Mar 2004, the minimum follow-up is now 5 yrs.

Results: Of the 9 pts, 3 were >60 yrs of age, 5 had no response to their last chemotherapy; 3 had transformed to a higher histology, 2 had an IPI score ≥3; 4 had BM involvement; 2 had elevated LDH, and 6 had tumors ≥5 cm in diameter. Of the 9 ongoing responders, 7 are still being followed for efficacy and safety. One pt relapsed at 6.9 yrs and continues to be followed for safety. One pt was noncompliant with clinical assessments and was withdrawn from study at 5.0 yrs (still in CR at last follow-up). The remaining 7 pts (~60% of complete responders) remain in continuous CR from 5.0–7.2 yrs. With an additional 37 mos’ follow-up, none of the 25 pts developed an elevated TSH level. The rate of hypothyroidism remains at 4.2%. Six pts developed 8 secondary malignancies (7 skin cancers, 1 GI carcinoma). With 3 yrs’ longer follow-up, no additional cases of MDS have been reported. The annualized incidence of MDS is 2.4%/yr.

Conclusions: In this pivotal study of BEXXAR, durable remissions of ≥5 yrs were achieved following only 1 wk of therapy in 9 heavily pretreated patients with LG, follicular, or transformed NHL who had many poor prognostic features for their disease. With 3 more yrs’ follow-up, long-term safety data remain basically unchanged, with no further reported cases of hypothyroidism or MDS.

Author notes

Corresponding author

2005, The American Society of Hematology

2004

Sign in via your Institution

Supplemental data